Skip to main content
ArticleOPEN ACCESS

Doubling down on PKC benefits allogeneic BMT

Blood
DOI: 10.1182/blood-2013-08-519900
1Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, using genetically deficient donor T cells or posttransplant pharmacologic inhibition, Haarberg et al have conclusively demonstrated that protein kinase C (PKC)-u and PKC-a each contribute to alloreactivity after experimental allogeneic bone marrow transplantation (BMT).

Cite

CITATION STYLE

APA

Fowler, D. H. (2013, October 3). Doubling down on PKC benefits allogeneic BMT. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2013-08-519900

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free